and Figure 2b of our previously published paper are incorrect as presented. The experiments were independently repeated with multiple donors and the new data are now presented as Figure 1c , Figure 1d and Figure 2b . The original conclusions drawn from these figures and the techniques described in the full manuscript remain the same. The VLP-Vpx technology provides an efficient and reliable method for introducing lentiviral shRNAs into resting CD4 T cells, especially into primary blood-derived lymphocytes that are in a deep resting state.
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